KATIE LUEBKE: Open Payments
NPI 1225644776 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$706 in 27 payments from 8 companies in 2025. Trend: 2023 $964 · 2024 $676 · 2025 $706
Food & beverage: $706
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $171 |
| Otsuka America Pharmaceutical, Inc. | 5 | $121 |
| Alkermes, Inc. | 5 | $119 |
| Vanda Pharmaceuticals Inc. | 4 | $106 |
| Janssen Pharmaceuticals, Inc | 2 | $59 |
| Neurocrine BioSciences, Inc. | 2 | $56 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $43 |
| E.R. Squibb & Sons, L.L.C. | 2 | $31 |
Products named: UZEDY, ABILIFY ASIMTUFII, FANAPT, ARISTADA, INVEGA SUSTENNA, INGREZZA, LYBALVI, CAPLYTA.
Industry payments across AZ — which companies pay providers there.
